When Investors Make Decisions in Teva Pharmaceutical Industries Limited American Depositary Shares TEVA Opportunities Surface ...

The most notable increase was Teva Pharmaceutical Industries Ltd (NYSE:TEVA), with an additional 7,569,450 shares, bringing the total to 8,997,400 shares. This adjustment represents a significant 530.

Mark Sabag, Executive Vice President of International Markets Commercial at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), recently sold a substantial block of the company's ordinary shares. The ...

TD Cowen raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $155 and keeps a Buy rating on the shares. The company ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 15.0% during the 4th quarter, according to its most ...

The main focus in Teva’s innovative portfolio continues to be neuroscience and immunology, with clinical trials for three key ...

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price objective reduced by Barclays from $28.00 to $26.00 in ...

2025 Non-GAAP EPS Guidance: $2.35 to $2.65. 2025 Free Cash Flow Guidance: $1.6 billion to $1.9 billion. Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported a 9% increase in revenue for 2024, ...